Oxford, UK – 03 September 2015. OGT, the molecular genetics company, today announces a strategic realignment of its commercial operations to fuel further growth in its high value genomics products portfolio. As part of this realignment, OGT will transfer its next generation sequencing services business to Source BioScience (LSE: SBS). Financial details were not disclosed.
Mike Evans, CEO of OGT commented, “Our strategic focus on the large and growing genomic medicine markets of cancer, molecular cytogenetics and reproductive health has delivered significant commercial growth. OGT’s genomics products portfolio has been growing at a compound annual growth rate of over 60% over the last four years and we have thus aligned our strategy and resources behind our genomics product business.”
OGT’s high-growth, product-focussed, strategy has been exemplified through the acquisition of CytoCell®, a leading provider of fluorescence in situ hybridisation (FISH) probes, in 2014, and its subsequent successful integration. OGT now has a strong, rapidly growing, core business comprised of CytoSure® arrays and CytoCell® FISH probes, with further product growth opportunities from its recently launched SureSeq™ range of cancer panels and its CytoSure Affirm non-invasive pre-natal test (NIPT) currently in clinical trials.
Mike Evans commented further on OGT’s transfer of its services business, “We will be providing our genetics analysis service customers with a high calibre alternative to OGT. We have worked closely with Source BioScience, well known as a trusted provider of state-of-the-art laboratory services, to ensure our customers will continue to receive best-in-class service and support, coupled with a seamless transition. Furthermore, OGT’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the consistent, high quality, genetic analysis that OGT provides.”
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Expansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.Read
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read
During these unprecedented times, OGT remains committed and ready to support you...Read